A federal jury in Boston ruled on Monday that Takeda Pharmaceutical employed anticompetitive tactics to prevent the launch of a generic alternative to Amitiza, its constipation treatment medication.
The jury determined that pharmacies, insurance companies, retailers and other parties suffered approximately $885 million in financial harm due to Takeda’s scheme to block the generic drug from entering the market.
The verdict represents a significant legal defeat for the pharmaceutical company in what was described as an antitrust case focused on delaying competition for the anti-constipation medication.
